Silent pheochromocytoma presenting as refractory hyperglycemia without classic adrenergic symptoms Authors: Shiven Bansal, Girish R Subramani, Sammy Elsayed Elsamra, Vivek Bansal Published: 2026 ABSTRACT AbstractWe report the case of a patient with uncontrolled and highly variable hyperglycemia and hypertension. He reported no history of headache, palpitations, or diaphoresis. Abdominal ultrasound and a triphasic computed tomography scan demonstrated a solid mass located medial and superior to the left kidney. Plasma and 24-hour urinary catecholamine levels confirmed a diagnosis of pheochromocytoma. Preoperative preparation included α-adrenergic and β-adrenergic blockade, along with salt and fluid loading. Continuous glucose monitoring and automated insulin delivery were used to stabilize glycemia. After multidisciplinary clearance of the surgery team, the patient underwent laparoscopic left adrenalectomy. Postoperatively, blood pressure and blood glucose normalized, allowing discontinuation of insulin and antihypertensive therapy. Histopathology and genetic testing confirmed a benign adrenal pheochromocytoma. A 3-month follow-up showed normalization of catecholamine levels, allowing the stabilization of blood glucose and blood pressure without medication. This case illustrates how fluctuating glycemia, initially attributed to poor adherence, was in fact secondary to catecholamine excess, underscoring the diagnostic challenge of pheochromocytoma in patients with coexisting metabolic disorders. Introduction Pheochromocytoma is a rare neuroendocrine tumor of the adrenal chromaffin cells, characterized by autonomous catecholamine secretion. Despite its rarity, unrecognized pheochromocytoma carries significant morbidity and perioperative risk [1]. Excess catecholamine produces cardiovascular and metabolic effects. The most common manifestations include hypertension, tachyarrhythmias, and the classic adrenergic triad of headache, palpitations, and diaphoresis. Catecholamines affect glucose metabolism through multiple mechanisms, including glucose intolerance and secondary diabetes mellitus [2, 3]. Severe or refractory hyperglycemia, although uncommon, may mask the underlying diagnosis [2, 4]. Early identification of pheochromocytoma enables definitive surgical resection, achieving complete biochemical and clinical remission. In addition, early knowledge of genetic status positively impacts management and clinical outcomes and improves survival among patients who develop metastases [5, 6]. We report an uncommon case of pheochromocytoma presenting with treatment-resistant hyperglycemia and refractory hypertension in the absence of classic adrenergic symptoms. The diagnosis was made incidentally after abdominal imaging revealed a large left adrenal tumor, with subsequent biochemical testing confirming a catecholamine-secreting tumor. Case presentation A 42-year-old male with a 2-year history of type 2 diabetes mellitus (T2DM) and a medical history of hypertension, hyperlipidemia, and poorly controlled hyperglycemia with a glycated hemoglobin (HbA1C) of 14.7% (SI: 137.16 mmol/mol; reference range: <5.7% [SI: <39 mmol/mol]) tested at point-of-care. His chronic medications included amlodipine besylate 10 mg/day, lisinopril-hydrochlorothiazide 12.5 mg/day, metformin hydrochloride 1000 mg twice daily, and atorvastatin calcium 10 mg/day. He reported a family history of type 1 diabetes mellitus and hypertension. His height was 1.78 m, weight 77.1 kg (body mass index: 24.4 kg/m2), blood pressure 138/109 mmHg, and pulse rate 97 beats per minute. He denied symptoms of palpitations, diaphoresis, or headaches. He was counseled on home blood pressure monitoring and further evaluation. The patient reported inconsistent self-monitoring of blood glucose, occasional alcohol consumption and light tobacco use, with no history of recreational drugs, caffeine intake, surgery, or allergies. He reported intermittent foot cramps, unintentional weight loss, and dietary indiscretion. Diagnostic assessment Between March 28, 2025 and April 25, 2025, laboratory evaluation revealed marked hyperglycemia (glucose:196 mg/dL [SI:10.88 mmol/L]; reference range: 70-100 mg/dL [SI:3.89-5.55 mmol/L]), with a normal C-peptide level of 1.2 ng/mL (SI: 0.40 nmol/L; reference range: 1.1-4.4 ng/mL [SI: 0.47-1.47 nmol/L]). Additional findings included mild hyponatremia (133 mEq/L [SI: 133 mmol/L]; reference range: 134-144 mEq/L [SI: 134-144 mEq/L]), hyperkalemia (5.4 mEq/L [SI: 5.4 mmol/L]; reference range 3.5-5.2 mEq/L [SI: 3.5-5.2 mmol/L]), hypochloremia (91 mEq/L [SI: 91 mmol/L]; reference range: 96-106 mEq/L [SI: 96-106 mmol/L]), and modest hypercalcemia (10.9 mg/dL [SI: 2.72 mmol/L]; reference range: 8.7-10.2 mg/dL [SI: 2.12-2.62 mmol/L]). Additional findings included hypovitaminosis D (21 ng/mL [SI: 52.42 nmol/L]; reference range: 30-80 ng/mL [SI: 94.85-199.68 nmol/L]), dyslipidemia (low-density lipoprotein (LDL): 125 mg/dL [SI: 3.23 mmol/L]; reference range: <100 mg/dL [SI: <2.59 mmol/L]), thrombocytosis (429 103/μL [SI: 429 × 109/L]; reference range: 150-400 103/μL [SI: 150-400 × 109/L]), and iron deficiency with elevated total iron-binding capacity, low transferrin saturation, and markedly elevated plasma renin activity (16.11 ng/mL/hour [SI: 16.11 μg/L/hour]; reference range: 0.17-5.38 ng/mL/hour [SI: 0.17-5.38 μg/L/hour]). Thyroid function (thyroid-stimulating hormone (TSH): 0.94 μIU/mL [SI. 0.94 mIU/L]; reference range: 0.45-4.50 μIU/mL [SI: 0.45-4.50 mIU/L], T4: 1.2 ng/dL [SI: 13.13 pmol/L]; reference range: 0.82-1.77 ng/dL [SI: 10.55-22.78 pmol/L]), triglycerides level (37 mg/dL [SI: 0.42 mmol/L]; reference range: <150 mg/dL [SI: <1.69 mmol/]), and renal function (estimated glomerular filtration rate (eGFR): 93 mL/min/1.73 m2 [SI: 93 mL/min/1.73 m2]; reference range >59 mL/min/1.73 m2 [SI: >59 mL/min/1.73 m2]) were within normal range (Table 1). Table 1Preoperative key metabolic, adrenal, and biochemical evaluationParametersMarch 25–April 28Aug 15–Sep 06Reference rangePlasma biochemical findings Intact PTH19 pg/mL(2.01 pmol/L)18 pg/mL1.91 pmol/L10-65 pg/mL(1.06-6.89 pmol/L) MagnesiumND1.90 mg/dL(0.78 mmol/L)1.6-2.3 mg/dL(80.70-0.91 mmol/L) ACTH14.2 pg/mL(3.12 pmol/L)12.1 pg/mL(2.66 pmol/L)7.2-63.3 pg/mL(1.6-13.9 pmol/L) DHEA-Sulfatea195.0 μg/dL(5.28 mmol/L)242.0 μg/dL(6.57 mmol/L)95-530 μg/dL(2.58-14.38 mmol/L) Cortisol (AM)11.0 μg/dL(303.49 nmol/L)13.7 μg/dL(377.98 nmol/L)6.2-19.4 μg/dL(138-635 nmol/L) HbA1CND 9.5% (80.33 mmol/mol) <5.7%(<39 mmol/mol) TSHaND0.78 μIU/mL(0.78 mIU/L)0.45-4.50 μIU/mL(0.45-4.50 mIU/L) T4, FreeaND1.02 ng/dL(13.13 pmol/L)0.82-1.77 ng/dL(10.55-22.78 pmol/L) NormetanephrineaND 2023.4 pg/mL (11047.76 pmol/L) <148.0 pg/mL(<808.08 pmol/L) MetanephrineND 731.2 pg/mL (3707.18 pmol/L) <88.0 pg/mL(<446.16 pmol/L) Renin activity 16.11 ng/mL/hour (16.11 μg/L/hour) 25.22 ng/mL/hour (25.22 μg/L/hour) 0.17-5.38 ng/mL/hour(0.17-5.38 μg/L/hour) Lipoprotein (a)ND 49.2 mg/dL (123.0 nmol/L) <30.0 mg/dL(<75.0 nmol/L)Urinary biochemical findings VMAND 14.0 mg/24 hour (70,63 μmol/24 hour) <7.5 mg/24 hour(<37.88 μmol/24 hour) EpinephrineND 402 mg/24 hour (2192.51 nmol/24 hour) <20 μg/24 hour(<109.08 nmol/24 hour) NorepinephrineND 1027 μg/24 hour (6070.60 nmol/24 hour) <135 μg/24 hour(<797.98 nmol/24 hour) NormetanephrineaND 3682 μg/24 hour (20206.82 nmol/24 hour) <600 μg/24 hour(<3292.8 nmol/24 hour) MetanephrineND 2932 μg/24 hour (14865.24 nmol/24 hour) <350 μg/24 hour(<1774.5 nmol/24 hour) Creatinine (24 hour)ND1072 mg/24 hour(9.48 mmol/24 hour)1000-2000 mg/24 hour(8.84-17.68 mmol/24 hour) Creatinine (sample)ND164.9 mg/dL(14.58 mmol/L)20-320 mg/dL(1.77-26.70 mmol/L) Cortisol, Free (24 hour)ND10 μg/24 hour(27.6 nmol/24 hour)5-64 μg/24 hour(13.8-176.64 nmol/24 hour) Cortisol, free (sample)ND16 μg/L(44.16 nmol/L)<30 μg/L(<82.8 nmol/L)Renal panel Glucose 196 mg/dL (10.88 mmol/L) 158 mg/dL (8.77 mmol/L) 70-100 mg/dL(3.89-5.55 mmol/L) BUN16 mg/dL(5.71 mmol/L)21 mg/dL(7.50 mmol/L)6-24 mg/dL(2.14-8.57 mmol/L) Creatinine (plasma)1.04 mg/dL(91.94 μmol/L)1.15 mg/dL(101.66 μmol/L)0.76-1.27 mg/dL(67.18-112.27 μmol/L) BUN/creatinine ratio15.38 (0.06)15.38 (0.06)7.89-18.90 (0.03-0.08) Sodium 133 mEq/L (133 mmol/L) 137 mEq/L(137 mmol/L)134-144 mEq/L(134-144 mmol/L) Potassium 5.4 mEq/L (5.4 mmol/L) 4.6 mEq/L(4.6 mmol/L)3.5-5.2 mEq/L(3.5-5.2 mmol/L) Chloride 91 mEq/L (91 mmol/L) 95 mEq/L (95 mmol/L) 96-106 mEq/L(96-106 mmol/L) Carbon dioxide, Total24 mEq/L(24 mmol/L)25 mEq/L(25 mmol/L)20-29 mEq/L(20-29 mmol/L) Calcium 10.9 mg/dL (2.72 mmol/L) 10.4 mg/dL (2.59 mmol/L) 8.5-10.5 mg/dL(2.12-2.62 mmol/L) Phosphorus3.9 mg/dL(1.26 mmol/L)3.5 mg/dL(1.13 mmol/L)2.8-4.19 mg/dL(0.81-1.45 mmol/L) Albumin5.1 g/dL(51.0 g/L)5.0 g/dL(50.0 g/L)4.1-5.1 g/dL(41-51 g/L) eGFR93 mL/min/1.73 m2(93 mL/min/1.73 m2)81 mL/min/1.73 m2(81 mL/min/1.73 m2)>59 mL/min/1.73 m2(>59 mL/min/1.73 m2)Preoperative biochemical testing was performed from March 25, 2025 to September 06, 2025. Results showed elevated plasma and urine catecholamines, along with elevated glucose and HbA1c, and an altered renal panel. Values are presented in conventional units (SI units).Abbreviations: ACTH, adrenocorticotropic hormone; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1C; NR, normal range; PTH, parathyroid hormone; T4, thyroxine; TSH, thyroid-stimulating hormone; VMA, vanillylmandelic acid. a The reference ranges for a man aged 40-49. Abnormal conventional values are shown in bold. Preoperative key metabolic, adrenal, and biochemical evaluation Preoperative biochemical testing was performed from March 25, 2025 to September 06, 2025. Results showed elevated plasma and urine catecholamines, along with elevated glucose and HbA1c, and an altered renal panel. Values are presented in conventional units (SI units). Abbreviations: ACTH, adrenocorticotropic hormone; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1C; NR, normal range; PTH, parathyroid hormone; T4, thyroxine; TSH, thyroid-stimulating hormone; VMA, vanillylmandelic acid. a The reference ranges for a man aged 40-49. Abnormal conventional values are shown in bold. A 28-day ambulatory glucose profile showed unstable glycemic control (Fig. 1), reflecting significant metabolic instability in the context of uncontrolled diabetes and hypertension. Continuous glucose monitoring pattern before adrenalectomy. Continuous glucose monitoring (CGM) visualization of a 28-day ambulatory glucose profile (AGP) report. The time-in-range panel showed a color-coded bar chart depicting time spent in target, high, and low glucose ranges, with expert-defined goals for type 1 and type 2 diabetes. The AGP graph aggregates glucose readings over 24 hours over 28 days: the solid line represents the median, darker shading indicates the central 50% of values, and lighter shading indicates the central 90%. Green shading corresponds to target range (70-180 mg/dL; SI: 3.89-10.0 mmol/L), yellow to high glucose (180-250 mg/dL; SI: 10.0-13.87 mmol/L), orange to very high (>250 mg/dL; SI: >13.87 mmol/L), red to low (54-70 mg/dL; SI: 3.0-3.89 mmol/L), and dark red to very low (<54 mg/dL; SI: <3.0 mmol/L). The glucose metrics panel displays average glucose, the glucose management indicator (GMI), and variability, along with report dates and CGM usage percentage. A routine ultrasound performed in the context of presumed diabetic pathology revealed a large adrenal mass. On July 11, 2025, a triphasic contrast-enhanced computed tomography (CT) scan of the abdomen and pelvis revealed a 61-mm, homogeneously enhancing mass medial and superior to the left kidney, distinct from renal and pancreatic structures (Fig. 2). The left adrenal gland was not separately visualized, suggesting an adrenal origin. On August 16, 2025, a 12.7 mCi dose of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)/CT showed mild metabolic activity. The lesion enhanced from 40 to 60 Hounsfield units across phases, without necrosis, hemorrhage, or macroscopic fat. Cross-sectional imaging of left adrenal gland. Abdominal CT scan obtained during the initial examination showed a well-defined adrenal lesion distinct from adjacent renal structures. (A) A cross-sectional precontrast-enhanced CT image shows a 61-cm mass (white arrow) medial and superior to the left kidney, distinct from renal and pancreatic structures. (B) A cross-sectional postcontrast-enhanced CT showed the lesion, without evidence of necrosis, hemorrhage, or macroscopic fat. Abbreviation: CT, computed tomography. Imaging features were not typical of a lipid-rich adenoma or a hypervascular pheochromocytoma. Given its size and indeterminate characteristics, surgical resection was recommended. Between August 15 and 28, 2025, biochemical testing revealed more than a 10-fold increase in plasma normetanephrine (2023.4 pg/mL [SI: 11047.76 pmol/L]; reference range <148.0 pg/mL [SI: <808.08 pmol/L]) and metanephrine (731.2 pg/mL [SI: 3707.18 pmol/L]; reference range: <88.0 pg/mL [SI: <446.16 pmol/L]). Urinary studies confirmed catecholamine hypersecretion: normetanephrine: 3682 µg/24 hour (SI: 20206.82 nmol/24 hour; reference range: <600 μg/24 hour [SI: <3292.8 nmol/24 hour]), metanephrine: 2932 µg/24 hour (SI: 14865.24 nmol/24 hour; reference range: <350 μg/24 hour [SI: <1774.5 nmol/24 hour]), norepinephrine: 1027 µg/24 hour (SI: 6070.60 nmol/24 hour; reference range: <135 μg/24 hour [SI: <797.98 nmol/24 hour]), epinephrine: 402 µg/24 hour (SI: 2192.51 nmol/24 hour; reference range: <20 μg/24 hour [SI: <109.08 nmol/24 hour]), and vanillylmandelic acid (VMA): 14 mg/24 hour (SI: 70,63 μmol/24 hour; reference range: <7.5 mg/24 hour [SI: <37.88 μmol/24 hour]). Morning cortisol levels were within normal limits. The differential diagnosis included Cushing syndrome; however, the hypercalcemia was attributed to dehydration in the context of excess catecholamines. Elevated plasma renin activity (25.22 ng/mL/hour [SI: 25.22 μg/L/hour]) with normal aldosterone levels and a low aldosterone/renin ratio ruled out primary hyperaldosteronism and was consistent with catecholamine-driven volume contraction. Biochemical testing confirmed pheochromocytoma as the underlying pathology (Table 1). Treatment Following confirmation of pheochromocytoma, the patient underwent standard preoperative medical optimization. For glycemic management, the patient transitioned to an Omnipod tubeless insulin pump in September 2025. Pump settings were consistent with insulin resistance at the time. The pump was continued perioperatively, with hourly intraoperative glucose checks (Fig. 3) and endocrinology oversight. Ambulatory glucose profile before and after adrenalectomy. Standardized AGP graphs derived from continuous glucose monitoring illustrate the patient's 24-hour glucose patterns before (A) and after (B) adrenalectomy. The patient was managed with an automated insulin pump. (A) The profile shows wide glycemic variability, reduced time in range (70-180 mg/dL: SI: 3.89-10.0 mmol/L), and frequent excursions above 250 mg/dL (SI: 13.87 mmol/L). (B) Following adrenalectomy, the AGP demonstrates improved stability, increased time in range, and a marked reduction in hyperglycemic episodes. Color-coded shading depicts time-in-range (green), high glucose (yellow/orange), and low glucose (red/dark red). The α-adrenergic blockade was initiated with doxazosin 1 mg orally at bedtime and titrated to a target of 8 mg twice daily, guided by blood pressure and orthostatic tolerance. Once adequate α-adrenergic blockade was achieved, β-adrenergic blockade was added with metoprolol tartrate 25 mg orally twice daily to prevent unopposed α-adrenergic stimulation. Concurrently, the patient followed a high-sodium diet and maintained liberal oral fluid intake to promote intravascular volume expansion and reduce the risk of perioperative hypotension. By September 26, the patient was on metoprolol 25 mg twice daily, lisinopril 5 mg daily, and doxazosin 8 mg twice daily, with home blood pressure readings around 101/69-102/76 mmHg, reflecting adequate α-blockade. Cardiac clearance was obtained. On September 27, 2025, a transthoracic echocardiogram showed a normal left ventricular cavity size and preserved global systolic function (ejection fraction 50-55%). The tricuspid valve was structurally normal, with only trace regurgitation. No additional abnormalities were identified. On October 1, 2025, the patient underwent elective laparoscopic left adrenalectomy. Intraoperative hemodynamics remained stable, and no hypertensive crises or arrhythmias occurred during tumor manipulation or resection. Gross and histopathologic examination of the partially fragmented adrenalectomy specimen revealed a pheochromocytoma measuring 65 × 53 × 38 mm (pathologic stage T2). Microscopic evaluation demonstrated focal capsular invasion and pleomorphic cytologic features without necrosis or increased mitotic activity. The tumor exhibited low-risk histopathologic characteristics, including a Pheochromocytoma of the Adrenal gland Scaled Score of 2 and a Ki-67 proliferation index <1%. No lymphovascular invasion was identified, and surgical margins were indeterminate due to specimen fragmentation. Outcome and follow-up The postoperative course was unremarkable. The patient reported no episodes of headache, palpitations, diaphoresis, visual disturbances, orthostatic symptoms, or any other adverse events. One week after surgery, biochemical evaluation showed that plasma catecholamine levels had normalized (normetanephrine 89.9 pg/mL [SI: 490.85 pmol/L], metanephrine <25 pg/mL [SI: <126.75 pmol/L]), glycemic control had improved substantially (HbA1c decreased to 5.9% [SI: 40.98 mmol/mol]), and renal function remained stable, consistent with resolution of catecholamine-mediated metabolic dysfunction (Table 2). Table 2Postoperative key metabolic, adrenal, and biochemical evaluationParametersPostadrenalectomyFollow-upReference rangePlasma Biochemical Findings Intact PTH18 pg/mL1.91 pmol/L18 pg/mL1.91 pmol/L10-65 pg/mL(1.06-6.89 pmol/L) Magnesium1.90 mg/dL(0.78 mmol/L)1.80 mg/dL(0.74 mmol/L)1.6-2.3 mg/dL(80.70-0.91 mmol/L) ACTH28.0 pg/mL(6.16 pmol/L)33.2 pg/mL(7.31 pmol/L)7.2-63.3 pg/mL(1.6-13.9 pmol/L) DHEA-Sulfatea146.0 μg/dL(3.96 mmol/L)206.0 μg/dL(5.58 mmol/L)95-530 μg/dL(2.58-14.38 mmol/L) Cortisol (AM)10.8 μg/dL(297.97 nmol/L)6.9 μg/dL(190.37 nmol/L)6.2-19.4 μg/dL(138-635 nmol/L) HbA1C 5.9% (40.98 mmol/mol) 5.4%(35.52 mmol/mol)<5.7%(<39 mmol/mol) TSHaND1.20 μIU/mL(1.20 mIU/L)0.45-4.50 μIU/mL(0.45-4.50 mIU/L) T4, FreeaND1.02 ng/dL(13.13 pmol/L)0.82-1.77 ng/dL(10.55-22.78 pmol/L) Normetanephrinea89.9 pg/mL(490.85 pmol/L)53.0 pg/mL(289.38 pmol/L)<148.0 pg/mL(<808.08 pmol/L) Metanephrine<25.0 pg/mL(<126.75 pmol/L)<25.0 pg/mL(<126.75 pmol/L)<88.0 pg/mL(<446.16 pmol/L) Renin ActivityND0.395 ng/mL/hour(0.395 μg/L/hour)0.17-5.38 ng/mL/hour(0.17-5.38 μg/L/hour) Lipoprotein (a)ND 35.4 mg/dL (87.6 nmol/L) <30.0 mg/dL(<75.0 nmol/L)Urinary biochemical findings VMANDND<7.5 mg/24 hour(<37.88 μmol/24 hour) EpinephrineNDND<20 μg/24 hour(<109.08 nmol/24 hour) NorepinephrineNDND<135 μg/24 hour(<797.98 nmol/24 hour) NormetanephrineaNDND<600 μg/24 hour(<3292.8 nmol/24 hour) MetanephrineNDND<350 μg/24 hour(<1774.5 nmol/24 hour) Creatinine (24 hour)NDND1000-2000 mg/24 hour(8.84-17.68 mmol/24 hour) Creatinine (sample)51.7 mg/dL(4.57 mmol/L)ND20-320 mg/dL(1.77-26.70 mmol/L) Cortisol, Free (24 hour)NDND5-64 μg/24 hour(13.8-176.64 nmol/24 hour) Cortisol, Free (sample)NDND<30 μg/L(<82.8 nmol/L) Renal Panel Glucose74 mg/dL(4.11 mmol/L)95 mg/dL(5.30 mmol/L)70-100 mg/dL(3.89-5.55 mmol/L) BUN11 mg/dL(3.93 mmol/L)13 mg/dL(4.64 mmol/L)6-24 mg/dL(2.14-8.57 mmol/L) Creatinine (plasma)0.87 mg/dL(76.91 μmol/L)1.01 mg/dL(89.28 μmol/L)0.76-1.27 mg/dL(67.18-112.27 μmol/L) BUN/Creatinine Ratio12.64 (0.05)12.87 (0.05)7.89-18.90 (0.03-0.08) Sodium139 mEq/L(139 mmol/L)139 mEq/L(139 mmol/L)134-144 mEq/L(134-144 mmol/L) Potassium4.3 mEq/L(4.3 mmol/L)4.3 mEq/L(4.3 mmol/L)3.5-5.2 mEq/L(3.5-5.2 mmol/L) Chloride98 mEq/L(98 mmol/L)99 mEq/L(99 mmol/L)96-106 mEq/L(96-106 mmol/L) Carbon dioxide, Total27 mEq/L(27 mmol/L)25 mEq/L(25 mmol/L)20-29 mEq/L(20-29 mmol/L) Calcium9.8 mg/dL(2.45 mmol/L)9.9 mg/dL(2.47 mmol/L)8.5-10.5 mg/dL(2.12-2.62 mmol/L) Phosphorus4.1 mg/dL(1.32 mmol/L)3.5 mg/dL(1.13 mmol/L)2.8-4.19 mg/dL(0.81-1.45 mmol/L) Albumin4.2 g/dL(42.0 g/L)4.5 g/dL(45.0 g/L)4.1-5.1 g/dL(41-51 g/L) eGFRND951 mL/min/1.73 m2(81 mL/min/1.73 m2)>59 mL/min/1.73 m2(>59 mL/min/1.73 m2)In October 2025, the patient underwent elective laparoscopic left adrenalectomy. Postoperative biochemical testing performed 1 week after adrenalectomy showed preserved pituitary–adrenal and thyroid function, with improved glycemic control. A 3-month follow-up biochemical test showed that plasma catecholamine levels were normalized after surgical resection. Values are presented in conventional units (SI units).Abbreviations: ACTH, adrenocorticotropic hormone; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1C; NR, normal range; PTH, parathyroid hormone; T4, thyroxine; TSH, thyroid-stimulating hormone; VMA, vanillylmandelic acid. a The reference ranges for a man aged 40-49. Abnormal values are shown in bold. Postoperative key metabolic, adrenal, and biochemical evaluation In October 2025, the patient underwent elective laparoscopic left adrenalectomy. Postoperative biochemical testing performed 1 week after adrenalectomy showed preserved pituitary–adrenal and thyroid function, with improved glycemic control. A 3-month follow-up biochemical test showed that plasma catecholamine levels were normalized after surgical resection. Values are presented in conventional units (SI units). Abbreviations: ACTH, adrenocorticotropic hormone; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1C; NR, normal range; PTH, parathyroid hormone; T4, thyroxine; TSH, thyroid-stimulating hormone; VMA, vanillylmandelic acid. a The reference ranges for a man aged 40-49. Abnormal values are shown in bold. After 3 months, glycemic control improved rapidly following tumor resection (HbA1c 5.4% [SI: 35.52 mmol/mol], glucose: 95 mg/dL [SI: 5.30 mmol/L]), allowing discontinuation of insulin therapy (Fig. 4). Continuous glucose monitoring showed normoglycemia without hypoglycemic episodes, and no rescue therapy was needed. Blood pressure remained within the normotensive range without antihypertensive therapy (Fig. 5). Plasma catecholamines showed complete biochemical remission, with normetanephrine 53 pg/mL (SI: 289.38 pmol/L) and metanephrine <25 pg/mL (SI: <126.75 pmol/L), while plasma renin activity was 0.395 ng/mL/hour (SI: 0.395 μg/L/hour). Adrenocorticotropic hormone (ACTH: 33.2 pg/mL [SI: 7.31 pmol/L]; reference range: 7.2-63.3 pg/mL [SI: 1.6-13.9 pmol/L]), intact parathyroid hormone (PTH: 18 pg/mL [SI: 1.91 pmol/L]; reference range: 10-65 pg/mL [SI: 1.06-6.89 pmol/L]), magnesium (1.8 mg/dL [SI: 0.74 mmol/L]; reference range: 1.6-2.3 mg/dL [SI: 0.70-0.91 mmol/L]), dehydroepiandrosterone sulfate (DHEA-sulfate: 206 μg/dL [SI: 5.58 mmol/L]; reference range: 95-530 μg/dL [SI: 2.58-14.38 mmol/L]), morning cortisol (6.9 µg/dL [SI: 190.37 nmol/L]; reference range: 6.2-19.4 μg/dL [SI: 138-635 nmol/L]), thyroid function (TSH 1.20 μIU/mL [SI: 1.20 mIU/L], free T4 1.02 ng/dL [SI: 13.13 pmol/L]), and the renal panel parameters were within normal limits. Glycemic control before and after adrenalectomy. Graph illustrating the trend in hemoglobin A1c (HbA1c) values over time (blue line), before and after adrenalectomy (dotted line). Preoperative measurements demonstrate poor glycemic control, while postoperative follow-up shows a marked reduction in HbA1c, with values falling into the normal range (light green line), consistent with resolution of catecholamine-induced hyperglycemia. Blood pressure before and after adrenalectomy. Graph depicting systolic (blue line) and diastolic blood pressure (orange line) measurements over time. Preoperative values demonstrate labile and treatment-resistant hypertension. Immediate adrenalectomy (dotted line) recordings show rapid normalization of blood pressure, followed by sustained normotension during serial follow-up without antihypertensive therapy. After 10 months, laboratory parameters remained within normal limits. Urinary catecholamine testing confirmed biochemical remission, with normetanephrine measured at 84 µg/g creatinine (SI: 51.8 nmol/mmol; reference range 80-583 µg/g [SI: 34-158 nmol/mmol]) and metanephrine at 200 µg/g creatinine (SI: 114.7 nmol/mmol; reference range <300 µg/g [SI: <172 nmol/mmol]). A multiple endocrine neoplasia type 1 (VistaSeq MEN1) panel, performed on blood-derived germline cells by next-generation sequencing (NGS) of coding regions and flanking splice sites (±10 bp), with deletion/duplication analysis by array CGH or MLPA (variants were classified according to ACMG standards), and Von Hippel–Lindau (VHL) DNA sequence amplification (coding sequence: isoform NM_000551) performed by Sanger sequencing, revealed no pathogenic sequence variants. These findings indicated stable endocrine function, preserved renal status, and sustained metabolic improvement following adrenalectomy. Discussion This case illustrates a rare presentation of pheochromocytoma. The normalization of glycemia following adrenalectomy confirms that hyperglycemia and hypertension were driven by catecholamine excess. Catecholamine excess impairs insulin secretion, stimulates glucagon release, increases hepatic gluconeogenesis, and induces peripheral insulin resistance through elevated free fatty acids. These mechanisms can produce dramatic metabolic derangements often misattributed to poor adherence or progressive T2DM [2, 3]. Pheochromocytoma is associated with the triad of headache, palpitations, and diaphoresis, yet metabolic manifestations are often overlooked [7]. Mild glucose intolerance occurs in 40-50% of cases, but severe hyperglycemia as the dominant feature is uncommon, with only a few reports describing such cases [7-10]. In this patient, persistently elevated HbA1c and postprandial hyperglycemia suggested uncontrolled diabetes, while imaging and biochemical testing revealed the underlying pheochromocytoma. Hyperglycemia resolved after adrenalectomy, confirming catecholamine excess as the driver of metabolic derangement and distinguishing tumor-related hyperglycemia from intrinsic β-cell dysfunction or progression of T2DM. This case underscores the need for systematic evaluation of metabolic abnormalities before invasive procedures. In addition, elevated albumin may have contributed to a component of pseudohypercalcemia, where the persistent elevation and subsequent normalization following tumor removal suggest a tumor-mediated etiology. Conversely, persistent lipoprotein(a) elevation may represent a baseline genetic risk for cardiovascular disease, unrelated to the pheochromocytoma [11]. Preoperative planning included α-adrenergic, β-blockade, and intravascular volume expansion. While guidelines recommend α-blockade for all hormonally secreting pheochromocytomas, recent evidence shows selective protocols equivalent to intraoperative control with less postoperative hypotension, reduced vasopressor requirements, and shorter hospital stay [12-14]. In this case, insulin therapy was safely discontinued, and the patient remains normotensive without antihypertensive medications, underscoring the reversibility of the metabolic and cardiovascular consequences of pheochromocytoma. This case is unique for several reasons. First, the patient presented with severe, refractory hyperglycemia as the dominant clinical feature, rather than the classic adrenergic symptoms. Second, serial laboratory monitoring followed the metabolic improvement after adrenalectomy. Third, the case highlights the importance of interdisciplinary collaboration to ensure patient safety and optimize outcomes. In conclusion, this report highlights a rare but reversible metabolic phenotype of pheochromocytoma. Clinicians should consider catecholamine-secreting tumors in unexplained hyperglycemia with labile or resistant hypertension. Timely recognition, tailored preoperative management, and interdisciplinary coordination are essential for safe surgery and metabolic improvement. Learning points Pheochromocytoma may present predominantly with severe, refractory hyperglycemia rather than the classical adrenergic triad. Pheochromocytoma may present predominantly with severe, refractory hyperglycemia rather than the classical adrenergic triad. Clinicians should maintain a high index of suspicion for catecholamine-secreting tumors in patients with sudden, disproportionate, or treatment-refractory hyperglycemia. Catecholamine excess can drive profound metabolic instability by impairing insulin secretion, increasing gluconeogenesis, and causing peripheral insulin resistance. Clinicians should maintain a high index of suspicion for catecholamine-secreting tumors in patients with sudden, disproportionate, or treatment-refractory hyperglycemia. Catecholamine excess can drive profound metabolic instability by impairing insulin secretion, increasing gluconeogenesis, and causing peripheral insulin resistance. Rapid normalization of glycemia and blood pressure following adrenalectomy underscores the reversibility of catecholamine-mediated metabolic dysfunction. Rapid normalization of glycemia and blood pressure following adrenalectomy underscores the reversibility of catecholamine-mediated metabolic dysfunction.